BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer 2015;13:225-30. [PMID: 25544725 DOI: 10.1016/j.clgc.2014.12.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Cimadamore A, Caliò A, Marandino L, Marletta S, Franzese C, Schips L, Amparore D, Bertolo R, Muselaers S, Erdem S, Ingels A, Pavan N, Pecoraro A, Kara Ö, Roussel E, Carbonara U, Campi R, Marchioni M; EAU-YAU Renal Cancer Working Group. Hot topics in renal cancer pathology: implications for clinical management. Expert Rev Anticancer Ther 2022;22:1275-87. [PMID: 36377655 DOI: 10.1080/14737140.2022.2145952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
4 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
5 Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shi H, Cao C, Wen L, Zhang L, Zhang J, Ma J, Shou J, Li C. Prognostic value of the ratio of maximum to minimum diameter of primary tumor in metastatic clear cell renal cell carcinoma. BMC Urol 2022;22:95. [PMID: 35787269 DOI: 10.1186/s12894-022-01047-y] [Reference Citation Analysis]
7 Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
8 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
9 Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
11 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
12 Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195-203. [PMID: 32712550 DOI: 10.1016/j.ejca.2020.06.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
13 Attalla K, Weng S, Voss MH, Hakimi AA. Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urol Clin North Am 2020;47:293-303. [PMID: 32600532 DOI: 10.1016/j.ucl.2020.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
14 Zhao Y, Chen H, Xie Y, Zhang C, Hou Y, Jin M. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS 2020;128:378-86. [PMID: 32048364 DOI: 10.1111/apm.13035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So AI, Drachenberg DE. Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Can Urol Assoc J 2020;14:24-30. [PMID: 31348746 DOI: 10.5489/cuaj.5941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wang YS, Shuang WB, Yin KQ, Tong XN, Xia MC, Yang HS. Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma. Mol Clin Oncol 2019;11:405-10. [PMID: 31475069 DOI: 10.3892/mco.2019.1900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Uçar M, Soyupek S, Oksay T, Özorak A, Güzel A, Öztürk SA, Demir M, Koşar A. Renal kitle nedeniyle radikal nefrektomi yapılan hastaların tümör karakteristiklerinin değerlendirilmesi; 18 yıllık sonuçlarımız. SDÜ Tıp Fakültesi Dergisi 2019. [DOI: 10.17343/sdutfd.460209] [Reference Citation Analysis]
18 Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
19 Delphine B, Damien A, Philippe B. Renal Cell Carcinoma with Sarcomatoid Features. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_9] [Reference Citation Analysis]
20 Wang Z, Zeng X, Chen R, Chen Z. Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Manag Res 2018;10:5339-47. [PMID: 30464630 DOI: 10.2147/CMAR.S176242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Zhang L, Wu B, Zha Z, Zhao H, Feng Y. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2018;10:1687-703. [PMID: 29970967 DOI: 10.2147/CMAR.S166710] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
22 Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz J, Barthélémy P. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. Clinical Genitourinary Cancer 2018;16:e577-86. [DOI: 10.1016/j.clgc.2017.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer 2017;83:237-46. [PMID: 28756136 DOI: 10.1016/j.ejca.2017.06.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
24 Molnar C, Tătaru O, Mărginean L, Borda A. Skeletal Muscle Metastases and Inferior Vena Cava Involvement in a Patient with Clear Cell Renal Cell Carcinoma and Sarcomatoid Differentiation. Journal of Interdisciplinary Medicine 2016;1:197-200. [DOI: 10.1515/jim-2016-0039] [Reference Citation Analysis]
25 Trudeau V, Larcher A, Sun M, Boehm K, Dell’oglio P, Sosa J, Tian Z, Fossati N, Briganti A, Shariat SF, Karakiewicz PI. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. World J Urol 2016;34:1429-36. [DOI: 10.1007/s00345-016-1780-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
26 Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 2015;33:427.e17-23. [PMID: 26004164 DOI: 10.1016/j.urolonc.2015.04.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]